Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
7 studies found for:    22658128 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Multiple Ascending Dose (MDX1105-01)
Condition: Cancer, Multiple Indications
Intervention: Biological: Anti-PDL-1 antibody
2 Not yet recruiting Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
Conditions: Mesothelioma;   Pleural Mesothelioma
Interventions: Drug: Concurrent Durvalumab;   Drug: Maintenance Durvalumab
3 Recruiting Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer
Condition: Small Cell Lung Cancer ( SCLC )
Interventions: Drug: Carboplatin;   Drug: Etoposide;   Biological: MPDL3280A
4 Recruiting Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
Conditions: Head and Neck Squamous Cell Carcinoma;   Metastatic Renal Cell Cancer;   Recurrent Head and Neck Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Renal Cell Carcinoma;   Recurrent Skin Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Lung Cancer;   Stage IV Skin Melanoma
Interventions: Radiation: Radiation Therapy (RT);   Drug: MK-3475
5 Not yet recruiting Phase I Study of Investigational Medicinal Products in Children With Relapsed/Refractory Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: Nivolumab;   Drug: Ch14.18/CHO
6 Recruiting Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: MK-3475;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed
7 Recruiting Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Condition: Neoplasms
Intervention: Genetic: Blood and tumor samples

Study has passed its completion date and status has not been verified in more than two years.